GAINERS
COMPANY SYMBOL LAST CHANGE PERCENT VOLUME
------- ------ ---- ------ ------- ------
Silence Therapeutics ADR SLN 19.58 10.90 125.58 71,907,945
Disc Medicine IRON 78.93 22.09 38.86 8,477,051
Exascale Labs Holdings XLAB 3.06 0.71 30.21 70,893,716
Annexon ANNX 4.01 0.60 17.60 6,351,602
Katapult Holdings KPLT 7.27 0.85 13.24 449,184
Agios Pharmaceuticals AGIO 34.90 3.58 11.43 1,972,982
Parabilis Medicines PBLS 25.35 2.60 11.43 2,142,521
Adagene ADR ADAG 2.29 0.23 11.17 308,790
Arcutis Biotherapeutics ARQT 31.89 3.07 10.65 5,792,940
Sagimet Biosciences SGMT 8.86 0.84 10.47 1,684,035
LOSERS
COMPANY SYMBOL LAST CHANGE PERCENT VOLUME
------- ------ ---- ------ ------- ------
EyePoint EYPT 0.44 -2.55 -85.28 183,465,576
XCHG ADR XCH 1.74 -0.87 -33.21 55,702
Black Hawk Acquisition BKHA 4.03 -1.98 -32.95 74,449
Iambic Therapeutics IAM 16.34 -7.47 -31.37 2,381,088
XIAO-I ADR AIXI 2.20 -0.72 -24.66 684,051
newcleo NWCL 4.75 -1.13 -19.22 819,415
Leverage 2X Lg GEMI Dly GEMG 3.52 -0.84 -19.20 78,612
DSC Holdings ADR DSC 3.52 -0.83 -19.08 33,587
Leverage 2X Lg BLSH Dly BLSG 1.86 -0.31 -14.14 52,038
Polestar Auto UK ADR PSNY 3.38 -0.52 -13.33 740,751
Only includes stocks with a prior day close of $2 a share
or higher and at least 2,000 shares traded today.
Data are delayed at least 15 minutes.
Source: WSJ Market Data Group
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments